Headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7636058777163 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Portola Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark (finance.yahoo.com)
- Portola Pharmaceuticals (PTLA) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- What You Must Know About Portola Pharmaceuticals Inc’s (NASDAQ:PTLA) Financial Strength (finance.yahoo.com)
- Portola Pharmaceuticals Inc (PTLA) Expected to Announce Quarterly Sales of $2.42 Million (americanbankingnews.com)
- Eye-Catching Shares – Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) – Alpha Beta Stock (alphabetastock.com)
A number of analysts recently issued reports on PTLA shares. Morgan Stanley reissued an “overweight” rating and set a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Oppenheimer set a $80.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, October 6th. Goldman Sachs Group assumed coverage on shares of Portola Pharmaceuticals in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 price target for the company. BidaskClub cut shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. Finally, Citigroup reaffirmed a “buy” rating and set a $74.00 price target on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $70.65.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.08. The company had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The business’s quarterly revenue was down 58.9% on a year-over-year basis. During the same period last year, the business earned ($1.64) EPS. equities research analysts forecast that Portola Pharmaceuticals will post -4.94 EPS for the current year.
In related news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Portola Pharmaceuticals (PTLA) Receives Daily News Impact Rating of 0.11” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://weekherald.com/2018/01/11/portola-pharmaceuticals-ptla-receives-daily-news-impact-rating-of-0-11.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.